Essex Bio-Technology Limited published its monthly return for November 2025, confirming that its authorized share capital remained at 1,000,000,000 ordinary shares, each with a par value of HKD 0.1, totaling HKD 100,000,000. The closing figure remained the same as the previous month with no alterations reported.

The number of issued ordinary shares also stayed unchanged at 567,006,000. Under the share option scheme approved on 9 June 2023, 57,064,900 share options were outstanding as of the end of November, with no new issuance or exercise during the period. The company reported no other movements in treasury shares, warrants, or convertible instruments.